pharma · Recurrent Pericarditis · Sjögren’s Disease · KNSA
Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 100 Hayden Ave, Lexington, Massachusetts 02421, US
- Founded
- 2015
- Employees
- 381
- Programs
- 14
- Drugs
- 7
- Patents
- 9
Kiniksa Pharmaceuticals International projects
10 ClinicalTrials.gov programs sponsored by Kiniksa Pharmaceuticals International.
Kiniksa Pharmaceuticals International has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Abiprubart
Kiniksa Pharmaceuticals International, plc
Sjögrens Disease
1 trial -
KPL-387
Kiniksa Pharmaceuticals International, plc
Well-Controlled Recurrent Pericarditis
1 trial -
KPL-387
Kiniksa Pharmaceuticals International, plc
Recurrent Pericarditis
1 trial -
KPL-404
Kiniksa Pharmaceuticals International, plc
Arthritis, Rheumatoid
1 trial -
KPL-404-C221
Kiniksa Pharmaceuticals International, plc
Sjögren’s Disease
1 trial -
KPL-716
Kiniksa Pharmaceuticals International, plc
Chronic Idiopathic Urticaria
1 trial -
KPL-914
Kiniksa Pharmaceuticals International, plc
Recurrent Pericarditis
1 trial -
Mavrilimumab
Kiniksa Pharmaceuticals International, plc
COVID-19
3 trials -
Vixarelimab
Kiniksa Pharmaceuticals International, plc
Prurigo Nodularis
1 trial -
mavrilimumab
Kiniksa Pharmaceuticals International, plc
Giant Cell Arteritis
1 trial
Frequently asked questions
How many clinical projects does Kiniksa Pharmaceuticals International have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.